Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Total Debt: 2016-2024

Historic Total Debt for Summit Therapeutics (SMMT) over the last 6 years, with Mar 2024 value amounting to $100.0 million.

  • Summit Therapeutics' Total Debt changed negligibly% to $100.0 million in Q1 2024 from the same period last year, while for Mar 2024 it was $100.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $100.0 million for FY2023, which is 79.78% down from last year.
  • Latest data reveals that Summit Therapeutics reported Total Debt of $100.0 million as of Q1 2024, which was down 0.00% from $100.0 million recorded in Q4 2023.
  • Over the past 5 years, Summit Therapeutics' Total Debt peaked at $494.5 million during Q4 2022, and registered a low of -$13.0 million during Q1 2020.
  • For the 3-year period, Summit Therapeutics' Total Debt averaged around $135.0 million, with its median value being $100.0 million (2024).
  • The largest annual percentage gain for Summit Therapeutics' Total Debt in the last 5 years was 299.12% (2023), contrasted with its biggest fall of 79.78% (2023).
  • Summit Therapeutics' Total Debt (Quarterly) stood at -$13.0 million in 2020, then reached $494.5 million in 2022, then crashed by 79.78% to $100.0 million in 2023, then remained steady at $100.0 million in 2024.
  • Its Total Debt was $100.0 million in Q1 2024, compared to $100.0 million in Q4 2023 and $100.0 million in Q2 2023.